Media & Investors

Basel, Switzerland, 07/06/2022

TargImmune Therapeutics AG, a privately owned Swiss-based biotechnology company dedicated to significantly improving the survival of cancer patients with their first-in-class Ta:RNA™ platform, today announced two major milestones - the appointment of Dr Marc Thommen as Head of Technical Development, and the successful completion of GLP/Tox studies....

Basel, Switzerland, 07/02/2022

TargImmune Therapeutics AG, a privately owned Swiss-based biotechnology company dedicated to significantly improving the survival of cancer patients by developing novel targeted anticancer treatments, today announced the further expansion of their management team with the appointment of Veronica Hersberger as Chief Medical Officer (CMO)....

Basel, Switzerland, 01/10/2021

TargImmune Therapeutics AG, a privately owned Swiss-based biotechnology company dedicated to significantly improving the survival of cancer patients by developing novel targeted anticancer treatments, today announced the appointment of Christoph Rentsch as full-time Chief Financial Officer (CFO)....

Basel, Switzerland, 09/07/2021

TargImmune Therapeutics AG (Basel, Switzerland), a privately held Swiss-based biotechnology company focused on the development of new medicines through the use of novel targeted immunotherapies, today announced that Peter Braun, who has extensive experience in the healthcare industry and most recently led the biopharmaceutical company Nordic Nanovector, has been appointed Chief Executive Officer (CEO), effective August 16, 2021. He will succeed Esteban Pombo-Villar, who has built the company over the past four years and will now focus on leading key projects in chemistry and biology as Chief Technology Officer (CTO)....